Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 17 of 1686 for:    CARBON DIOXIDE AND dioxide

Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02381795
Recruitment Status : Terminated (Terminated at the request of the financial sponsor.)
First Posted : March 6, 2015
Results First Posted : May 1, 2018
Last Update Posted : August 14, 2018
Sponsor:
Collaborator:
Capnia, Inc.
Information provided by (Responsible Party):
Cady, Roger, M.D.

Tracking Information
First Submitted Date  ICMJE March 3, 2015
First Posted Date  ICMJE March 6, 2015
Results First Submitted Date  ICMJE March 28, 2018
Results First Posted Date  ICMJE May 1, 2018
Last Update Posted Date August 14, 2018
Study Start Date  ICMJE July 2015
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 16, 2018)
Headache Pain Intensity [ Time Frame: Immediately preceeding treatment to 30 minutes post-treatment ]
Greatest change in headache pain intensity post treatment (at any time point within 30 minutes of Nasal CO2 administration) - pre-treatment. Pain intensity will be measured as follows: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain. Full Range values were calculated change values, and do not represent the full range of the scale.
Original Primary Outcome Measures  ICMJE
 (submitted: March 3, 2015)
Headache Pain Intensity [ Time Frame: Immediately preceeding treatment to 30 minutes post-treatment ]
Greatest change from pre-treatment headache pain intensity to post treatment at any time point within 30 minutes of Nasal CO2 administration. Pain intensity will be measured as follows: 0 = no pain, 1 = mild pain, 2 = moderate pain, and 3 = severe pain.
Change History Complete list of historical versions of study NCT02381795 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
Official Title  ICMJE An Open Label, Pilot Study Evaluating the Efficacy and Safety of the Use of Nasal Carbon Dioxide for the Treatment of Episodic Cluster Headache
Brief Summary This is an open label, investigator-sponsored, pilot study. Subjects agreeing to participate in the study and meeting the eligibility criteria assessed at the screening visit will be enrolled in the study. The length of time between screening and treatment will last between 0 days to a maximum of 12 weeks. Subjects who enter the screening phase during a cluster headache episode and meet the study eligibility criteria can immediately enter the treatment phase and may opt to treat their cluster headache episode in the clinic. Subjects who are not in a cluster headache episode, who meet initial screening eligibility criteria, can remain in the screening phase for up to 12 weeks until their next cluster episode begins. Upon initiation of a cluster headache episode, subjects will enter the treatment period. Subjects will be trained on the proper use of the hand-held dispenser containing carbon dioxide (CO2 )calibrated to deliver 0.5 standard liters per minute (SLPM). This dispenser will be provided for use in the clinic or home. Subjects will be instructed to use the nasal CO2 dispenser, 10 seconds/nostril, as needed up to 6 times to treat one attack. Each dose must be separated by 3-5 minutes. Subjects should treat only one attack in a 24-hour period. Subjects may treat up to three cluster headache attacks during the treatment phase of this study. One hour after the first dose, subjects can choose to treat with investigator-approved rescue medication. Subjects will be asked to complete an online diary after the completion of the dosing. Diary assessments will collect pain severity, nasal CO2 usage, acute medication usage, satisfaction of treatment, number of cluster attacks, and unusual symptoms. Subjects will be contacted by phone within 3 days of the first use of the nasal CO2 dispenser to assess adverse events (AEs) and medication usage. A total of 25 subjects will enter the treatment period and be instructed to treat up to 3 cluster headaches with nasal CO2. Within 7 days of treating their last cluster headache episode, subjects will return for an end of study visit.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Cluster Headache
Intervention  ICMJE Drug: Nasal Carbon Dioxide
Study Arms  ICMJE Experimental: Nasal Carbon Dioxide
0.17 liters (L) of carbon dioxide (CO2) will be delivered through two 10 second administrations in each nostril, up to 6 times, to treat one attack (total of 1.0 L CO2). Subjects may treat up to three cluster headache attacks during the treatment phase of this study (total of 3.0 L (CO2).
Intervention: Drug: Nasal Carbon Dioxide
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: April 12, 2017)
10
Original Estimated Enrollment  ICMJE
 (submitted: March 3, 2015)
25
Actual Study Completion Date  ICMJE April 2017
Actual Primary Completion Date April 2017   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male and female, 18 years of age and older.
  • History of episodic cluster headache, as defined by International Classification of Headache Disorders (ICHD), third edition, beta version guidelines (ICHD-3 beta, Cephalalgia 2013).
  • History of cluster headache attack-free remission periods lasting > 1 month within the previous year.
  • Stable on medications, including those for the treatment of cluster headache prevention/prophylaxis, for at least 60 days prior to baseline (including, but not limited to, verapamil, lithium, melatonin, any anticonvulsant, any systemic corticosteroid or steroid injection, occipital nerve block, other cranial or extracranial nerve block, or any neurostimulation treatment).

Note: Subjects are allowed to use their usual standard of care for the acute/abortive treatment of acute cluster attacks 60 or more minutes after the initial dose, limited to the following: triptans; high-flow oxygen.

  • If female and of childbearing potential, have a negative urine pregnancy test at the time of Screening.

    a. To not be considered childbearing potential a subject must be surgically sterile, have had a hysterectomy or tubal ligation, post-menopausal for at least 1 year, or otherwise incapable of pregnancy.

  • Capable of completing online headache diary with access to internet.
  • Able to provide written Informed Consent.

Exclusion Criteria:

  • Recent nasal/midface trauma (< 3 months)
  • Recent nasal/sinus surgery (< 3 months).
  • Severe respiratory distress in the last 6 months.
  • Neoplasm such as Angiofibroma, sinus tumor, granuloma.
  • Nasal congestion present more than 10 days with fever (temperature ≥ 100.4 °F) and nasal mucous is an abnormal color.
  • Surgery to treat cluster headache.
  • History of aneurysm, intracranial hemorrhage, brain tumors or significant head trauma.
  • Structural intracranial or cervical vascular lesions that may potentially cause headache attacks.
  • Other significant pain problems (including cancer pain, fibromyalgia, and trigeminal neuralgia) that might confound the study assessments in the investigator opinion.
  • Psychiatric disorder, which in the opinion of the Investigator, may interfere with the study.
  • Pregnant, actively trying to become pregnant, or breastfeeding, and/or is unwilling to use an accepted form of birth control.
  • Skin around and inside the nasal passage that is dry, cracked, oozing, or bleeding.
  • Recurrent nose bleeds, which in the opinion of the Investigator, may interfere with the study.
  • Is participating in any other therapeutic clinical investigation or has participated in a clinical trial and received treatment in the preceding 30 days.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02381795
Other Study ID Numbers  ICMJE 15-001CA
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Cady, Roger, M.D.
Study Sponsor  ICMJE Cady, Roger, M.D.
Collaborators  ICMJE Capnia, Inc.
Investigators  ICMJE Not Provided
PRS Account Cady, Roger, M.D.
Verification Date July 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP